Published in J Immunol on September 01, 1998
A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J Virol (2005) 2.44
Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J Virol (2003) 1.60
GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. Virology (2007) 1.52
Antigenicity, Immunogenicity and Protective Efficacy of Three Proteins Expressed in the Promastigote and Amastigote Stages of Leishmania infantum against Visceral Leishmaniasis. PLoS One (2015) 1.40
Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. J Clin Invest (2004) 1.39
Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites. Infect Immun (2005) 1.34
DNA vaccination against tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity. Infect Immun (2000) 1.33
Induction of protective immunity against Schistosoma mansoni via DNA priming and boosting with the large subunit of calpain (Sm-p80): adjuvant effects of granulocyte-macrophage colony-stimulating factor and interleukin-4. Infect Immun (2003) 1.09
Protection of rhesus macaques against lethal Plasmodium knowlesi malaria by a heterologous DNA priming and poxvirus boosting immunization regimen. Infect Immun (2002) 1.07
Persistence of protective immunity to malaria induced by DNA priming and poxvirus boosting: characterization of effector and memory CD8(+)-T-cell populations. Infect Immun (2002) 1.06
Dendritic cells can initiate protective immune responses against malaria. Infect Immun (2001) 1.04
The MIC3 gene of Toxoplasma gondii is a novel potent vaccine candidate against toxoplasmosis. Infect Immun (2003) 1.02
Multistage multiantigen heterologous prime boost vaccine for Plasmodium knowlesi malaria provides partial protection in rhesus macaques. Infect Immun (2001) 1.02
Granulocyte-macrophage colony-stimulating factor-deficient mice have impaired resistance to blood-stage malaria. Infect Immun (2001) 1.01
Genetic vaccination against malaria infection by intradermal and epidermal injections of a plasmid containing the gene encoding the Plasmodium berghei circumsporozoite protein. Infect Immun (2000) 1.00
Novel antigen identification method for discovery of protective malaria antigens by rapid testing of DNA vaccines encoding exons from the parasite genome. Infect Immun (2004) 0.96
Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA. Hum Vaccin Immunother (2012) 0.95
Recent Developments in Preclinical DNA Vaccination. Vaccines (Basel) (2014) 0.85
Immunogenicity and protective efficacy of a Plasmodium yoelii Hsp60 DNA vaccine in BALB/c mice. Infect Immun (2001) 0.83
Enhancing efficacy of HIV gag DNA vaccine by local delivery of GM-CSF in murine and macaque models. J Interferon Cytokine Res (2006) 0.83
DNA-protein immunization using Leishmania peroxidoxin-1 induces a strong CD4+ T cell response and partially protects mice from cutaneous leishmaniasis: role of fusion murine granulocyte-macrophage colony-stimulating factor DNA adjuvant. PLoS Negl Trop Dis (2014) 0.81
DNA immunization as an efficient strategy for vaccination. Avicenna J Med Biotechnol (2009) 0.81
Mammalian granulocyte-macrophage colony-stimulating factor and some CpG motifs have an effect on the immunogenicity of DNA and subunit vaccines in fish. Immunology (1999) 0.81
Immunization with two recombinant Bacillus Calmette-Guérin vaccines that combine the expression of multiple tandem repeats of mucin-1 and colony stimulating-factor suppress breast tumor growth in mice. J Cancer Res Clin Oncol (2010) 0.81
Effects of type I interferons on the adjuvant properties of plasmid granulocyte-macrophage colony-stimulating factor in vivo. J Virol (2007) 0.79
Genetic vaccination approaches against malaria based on the circumsporozoite protein. Wien Klin Wochenschr (2006) 0.77
Co-administration of plasmid-encoded granulocyte-macrophage colony-stimulating factor increases human immunodeficiency virus-1 DNA vaccine-induced polyfunctional CD4+ T-cell responses. Mem Inst Oswaldo Cruz (2015) 0.75
High Doses of GM-CSF Inhibit Antibody Responses in Rectal Secretions and Diminish Modified Vaccinia Ankara/Simian Immunodeficiency Virus Vaccine Protection in TRIM5α-Restrictive Macaques. J Immunol (2016) 0.75
CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (1995) 12.24
Diagnosis of malaria by detection of Plasmodium falciparum HRP-2 antigen with a rapid dipstick antigen-capture assay. Lancet (1994) 6.01
Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity. Science (2011) 4.72
CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc Natl Acad Sci U S A (1988) 4.67
DNA vaccines: immunology, application, and optimization*. Annu Rev Immunol (2000) 4.51
Chromosome 2 sequence of the human malaria parasite Plasmodium falciparum. Science (1998) 3.83
Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am J Trop Med Hyg (1997) 3.61
Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science (1998) 3.46
Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. Am J Trop Med Hyg (1991) 3.31
We are overinterpreting the predictive value of serum follicle-stimulating hormone levels. Fertil Steril (1999) 3.21
Varicella vaccination: evidence for frequent reactivation of the vaccine strain in healthy children. Nat Med (2000) 3.07
Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet (1991) 3.01
Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet (1987) 2.98
The complexity of protective immunity against liver-stage malaria. J Immunol (2000) 2.92
Systemic autoimmune disease arises from polyclonal B cell activation. J Exp Med (1987) 2.71
Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J Immunol (2001) 2.61
Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci U S A (1994) 2.58
Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge. J Infect Dis (1997) 2.55
Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol (2001) 2.49
Reduction of mortality in chloramphenicol-treated severe typhoid fever by high-dose dexamethasone. N Engl J Med (1984) 2.24
Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J Immunol (1999) 2.23
An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum Gene Ther (1996) 2.23
Efficacy of murine malaria sporozoite vaccines: implications for human vaccine development. Science (1987) 2.17
Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity. J Exp Med (1996) 2.15
Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications. Science (1987) 2.11
Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. Am J Trop Med Hyg (1986) 2.09
Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes. Science (1989) 2.09
Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria-infected hepatocytes. J Exp Med (1990) 2.09
A shotgun optical map of the entire Plasmodium falciparum genome. Nat Genet (1999) 2.04
Genomic DNA released by dying cells induces the maturation of APCs. J Immunol (2001) 2.03
Characterization of Plasmodium falciparum sporozoite surface protein 2. Proc Natl Acad Sci U S A (1992) 2.00
Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein. Science (1991) 1.94
Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc Natl Acad Sci U S A (1998) 1.93
IL-12 and NK cells are required for antigen-specific adaptive immunity against malaria initiated by CD8+ T cells in the Plasmodium yoelii model. J Immunol (1999) 1.92
Characterization of Plasmodium yoelii monoclonal antibodies directed against stage-specific sporozoite antigens. Infect Immun (1987) 1.87
Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine. J Infect Dis (1995) 1.87
Bone marrow aspirate culture superior to streptokinase clot culture and 8 ml 1:10 blood-to-broth ratio blood culture for diagnosis of typhoid fever. Am J Trop Med Hyg (1986) 1.86
Plasmodium falciparum-infected Anopheles stephensi inconsistently transmit malaria to humans. Am J Trop Med Hyg (1990) 1.85
Cloning of a gene involved in regulation of exotoxin A expression in Pseudomonas aeruginosa. Infect Immun (1986) 1.84
Human immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation. J Clin Invest (1992) 1.84
Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles. Immunity (1997) 1.84
Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil. J Infect Dis (1995) 1.83
HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLA class II alleles. J Immunol (2000) 1.82
Spontaneous second trimester uterine rupture after classical cesarean. Obstet Gynecol (2000) 1.79
Monoclonal, but not polyclonal, antibodies protect against Plasmodium yoelii sporozoites. J Immunol (1991) 1.78
Antibodies against the Plasmodium falciparum receptor binding domain of EBA-175 block invasion pathways that do not involve sialic acids. Infect Immun (2000) 1.77
Interleukin 12 induction of interferon gamma-dependent protection against malaria. Proc Natl Acad Sci U S A (1994) 1.77
Research toward vaccines against malaria. Nat Med (1998) 1.76
Interferon (IFN) consensus sequence-binding protein, a transcription factor of the IFN regulatory factor family, regulates immune responses in vivo through control of interleukin 12 expression. J Exp Med (1997) 1.73
IFN-gamma inhibits development of Plasmodium berghei exoerythrocytic stages in hepatocytes by an L-arginine-dependent effector mechanism. J Immunol (1991) 1.73
Increased frequency of obstructive airway abnormalities with long-term tracheostomy. Chest (1993) 1.71
Tropical medicine. BMJ (2000) 1.67
Age-dependent susceptibility to severe disease with primary exposure to Plasmodium falciparum. J Infect Dis (1998) 1.65
Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. Proc Natl Acad Sci U S A (2001) 1.63
A T cell clone directed at the circumsporozoite protein which protects mice against both Plasmodium yoelii and Plasmodium berghei. J Immunol (1992) 1.62
Human cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein. Proc Natl Acad Sci U S A (1991) 1.61
Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer. J Clin Oncol (1995) 1.60
Exploring the transcriptome of the malaria sporozoite stage. Proc Natl Acad Sci U S A (2001) 1.59
Severe anemia in young children after high and low malaria transmission seasons in the Kassena-Nankana district of northern Ghana. Am J Trop Med Hyg (2000) 1.58
Malaria sporozoites and circumsporozoite proteins bind specifically to sulfated glycoconjugates. J Cell Biol (1992) 1.58
Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J Immunol (1999) 1.58
Incidence of symptomatic and asymptomatic Plasmodium falciparum infection following curative therapy in adult residents of northern Ghana. Am J Trop Med Hyg (2001) 1.57
Distinct patterns of cytokine secretion characterize new onset synovitis versus chronic rheumatoid arthritis. J Rheumatol (1998) 1.55
Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. Infect Immun (2001) 1.55
Diagnostic value of serum hCG on the outcome of pregnancy of unknown location: a systematic review and meta-analysis. Hum Reprod Update (2012) 1.52
Immunity to malaria and naturally acquired antibodies to the circumsporozoite protein of Plasmodium falciparum. N Engl J Med (1986) 1.51
Further consideration of the clonal nature of Salmonella typhi: evaluation of molecular and clinical characteristics of strains from Indonesia and Peru. J Clin Microbiol (1992) 1.50
Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen. J Infect Dis (2000) 1.48
Sterile protection of monkeys against malaria after administration of interleukin-12. Nat Med (1997) 1.48
Activation of target-tissue immune-recognition molecules by double-stranded polynucleotides. Proc Natl Acad Sci U S A (1999) 1.48
Plasmodium yoelii and Plasmodium berghei: isolation of infected erythrocytes from blood by colloidal silica gradient centrifugation. Exp Parasitol (1980) 1.48
Antigen-specific suppressor T lymphocytes in human lymphatic filariasis. N Engl J Med (1982) 1.47
Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. J Immunol (1996) 1.46
Studies of consomic mice bearing the Y chromosome of the BXSB mouse. J Immunol (1985) 1.44
Sequence of the immunodominant epitope for the surface protein on sporozoites of Plasmodium vivax. Science (1985) 1.44
Inability of malaria vaccine to induce antibodies to a protective epitope within its sequence. Science (1991) 1.43
Determining liver stage parasite burden by real time quantitative PCR as a method for evaluating pre-erythrocytic malaria vaccine efficacy. Mol Biochem Parasitol (2001) 1.40
A malaria sporozoite surface antigen distinct from the circumsporozoite protein. Bull World Health Organ (1990) 1.40
Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia. Clin Infect Dis (2001) 1.40
Duodenal string-capsule culture compared with bone-marrow, blood, and rectal-swab cultures for diagnosing typhoid and paratyphoid fever. J Infect Dis (1984) 1.38
Cellular mechanisms of nonspecific immunity to intracellular infection: cytokine-induced synthesis of toxic nitrogen oxides from L-arginine by macrophages and hepatocytes. Immunol Lett (1990) 1.36
Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am J Trop Med Hyg (1993) 1.34
Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine (2000) 1.34
Protection against malaria by Plasmodium yoelii sporozoite surface protein 2 linear peptide induction of CD4+ T cell- and IFN-gamma-dependent elimination of infected hepatocytes. J Immunol (1996) 1.34